p53 restoration in small cell lung cancer identifies a latent cyclophilin-dependent necrosis mechanism

被引:3
|
作者
Acosta, Jonuelle [1 ,2 ]
Li, Qinglan [1 ]
Freeburg, Nelson F. [1 ,2 ]
Murali, Nivitha [1 ]
Indeglia, Alexandra [3 ]
Grothusen, Grant P. [1 ,2 ]
Cicchini, Michelle [1 ]
Mai, Hung [1 ]
Gladstein, Amy C. [1 ,2 ]
Adler, Keren M. [1 ,2 ]
Doerig, Katherine R. [1 ,2 ]
Li, Jinyang [1 ]
Ruiz-Torres, Miguel [1 ]
Manning, Kimberly L. [1 ]
Stanger, Ben Z. [2 ,4 ]
Busino, Luca [1 ,2 ,4 ]
Murphy, Maureen [2 ,5 ]
Wan, Liling [1 ,2 ,4 ]
Feldser, David M. [1 ,2 ,4 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA USA
[2] Univ Penn, Perelman Sch Med, Cell & Mol Biol Grad Grp, Philadelphia, PA USA
[3] Univ Penn, Perelman Sch Med, Biochem & Mol Biophys Grad Grp, Philadelphia, PA USA
[4] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA USA
[5] Wistar Inst Anat & Biol, Program Mol & Cellular Oncogenesis, Philadelphia, PA USA
关键词
MITOCHONDRIAL PERMEABILITY TRANSITION; TUMOR SUPPRESSION; BINDING; EXPRESSION; LANDSCAPE; INACTIVATION; PROGRESSION; INHIBITION; SENESCENCE; ISOMERASE;
D O I
10.1038/s41467-023-40161-9
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The p53 tumor suppressor regulates multiple context-dependent tumor suppressive programs. Although p53 is mutated in similar to 90% of small cell lung cancer (SCLC) tumors, how p53 mediates tumor suppression in this context is unknown. Here, using a mouse model of SCLC in which endogenous p53 expression can be conditionally and temporally regulated, we show that SCLC tumors maintain a requirement for p53 inactivation. However, we identify tumor subtype heterogeneity between SCLC tumors such that p53 reactivation induces senescence in a subset of tumors, while in others, p53 induces necrosis. We pinpoint cyclophilins as critical determinants of a p53-induced transcriptional program that is specific to SCLC tumors and cell lines poised to undergo p53-mediated necrosis. Importantly, inhibition of cyclophilin isomerase activity, or genetic ablation of specific cyclophilin genes, suppresses p53-mediated necrosis by limiting p53 transcriptional output without impacting p53 chromatin binding. Our study demonstrates that intertumoral heterogeneity in SCLC influences the biological response to p53 restoration, describes a cyclophilin-dependent mechanism of p53-regulated cell death, and uncovers putative mechanisms for the treatment of this most-recalcitrant tumor type. p53 inactivation is nearly universal in small-cell lung cancer (SCLC), but its tumor suppressive role in this cancer type is poorly understood. Here the authors show that intertumoral heterogeneity in SCLC influences the biological mechanisms of p53-mediated tumor suppression and identify a role for cyclophilins in p53-dependent necrotic cell death.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] NFIB overexpression cooperates with Rb/p53 deletion to promote small cell lung cancer
    Wu, Nan
    Jia, Deshui
    Ibrahim, Ali H.
    Bachurski, Cindy J.
    Gronostajski, Richard M.
    MacPherson, David
    ONCOTARGET, 2016, 7 (36) : 57514 - 57524
  • [32] p53 dependent chemopreventive and theraputic activity on lung cancer by Pterostilbene
    Lee, H.
    Kim, Y.
    Ryu, J. H.
    Kim, W. Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S66 - S66
  • [33] The utility of p53 immunostaining of transbronchial biopsy specimens of lung cancer: p53 overexpression predicts poor prognosis and chemoresistance in advanced non-small cell lung cancer
    Kawasaki, M
    Nakanishi, Y
    Kuwano, K
    Yatsunami, J
    Takayama, K
    Hara, N
    CLINICAL CANCER RESEARCH, 1997, 3 (07) : 1195 - 1200
  • [34] DEVELOPMENT OF ANTIBODIES AGAINST P53 IN LUNG-CANCER PATIENTS APPEARS TO BE DEPENDENT ON THE TYPE OF P53 MUTATION
    WINTER, SF
    MINNA, JD
    JOHNSON, BE
    TAKAHASHI, T
    GAZDAR, AF
    CARBONE, DP
    CANCER RESEARCH, 1992, 52 (15) : 4168 - 4174
  • [35] P53 codon 72 polymorphism increases the risk of somatic P53 gene mutations in non-small cell lung cancer (NSCLC)
    Szymanowska, A
    Jassem, E
    Dziadziuszko, R
    Borg, A
    Limon, J
    Kobierska-Gulida, G
    Skokowski, J
    Jassem, J
    LUNG CANCER, 2005, 49 : S75 - S75
  • [36] Relation between P53 codon 72 polymorphism and somatic P53 gene mutation in non-small cell lung cancer (NSCLC)
    Jassem, J.
    Szymanowska, A.
    Jassem, E.
    Dziadziuszko, R.
    Borg, A.
    Limon, J.
    Kobierska-Gulida, G.
    Skokowski, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 336 - 336
  • [37] Growth inhibitory role of the p53 activator SCH 529074 in non-small cell lung cancer cells expressing mutant p53
    Nenkov, Miljana
    Ma, Yunxia
    Haase, Daniela
    Zhou, Zhongwei
    Li, Yong
    Petersen, Iver
    Lu, Guanghua
    Chen, Yuan
    ONCOLOGY REPORTS, 2020, 43 (06) : 2073 - 2082
  • [38] Stage-specific sensitivity to p53 restoration during lung cancer progression
    David M. Feldser
    Kamena K. Kostova
    Monte M. Winslow
    Sarah E. Taylor
    Chris Cashman
    Charles A. Whittaker
    Francisco J. Sanchez-Rivera
    Rebecca Resnick
    Roderick Bronson
    Michael T. Hemann
    Tyler Jacks
    Nature, 2010, 468 : 572 - 575
  • [39] Stage-specific sensitivity to p53 restoration during lung cancer progression
    Feldser, David M.
    Kostova, Kamena K.
    Winslow, Monte M.
    Taylor, Sarah E.
    Cashman, Chris
    Whittaker, Charles A.
    Sanchez-Rivera, Francisco J.
    Resnick, Rebecca
    Bronson, Roderick
    Hemann, Michael T.
    Jacks, Tyler
    NATURE, 2010, 468 (7323) : 572 - U249
  • [40] Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status
    Van den Bossche, Jolien
    Domen, Andreas
    Peeters, Marc
    Deben, Christophe
    De Pauw, Ines
    Jacobs, Julie
    De Bruycker, Sven
    Specenier, Pol
    Pauwels, Patrick
    Vermorken, Jan Baptist
    Lardon, Filip
    Wouters, An
    CANCERS, 2019, 11 (12)